心力衰竭疾病管理对β受体阻滞剂和血管紧张素转换酶抑制剂类药物使用的影响被引量：2

下载PDF

导出

摘要目的研究临床药师参与慢性心力衰竭疾病管理对于β受体阻滞剂和血管紧张素转换酶抑制剂类药物使用的影响。方法选取2012年8月-2013年5月住院的患者108例,随机分为心力衰竭疾病管理组58例和对照组50例,临床药师对疾病管理组患者进行住院期间个体化用药方案制定、用药教育,出院后电话随访,对照组给予常规治疗。结果在1年的随访中,心力衰竭疾病管理组60.3%(35/58)患者使用β受体阻滞剂;对照组46.0%(23/50)使用β受体阻滞剂,2组比较差异有统计学意义(P<0.05);心力衰竭疾病管理组82.8%(48/58)患者使用ACEI/ARB;对照组64.0%(32/50)患者使用ACEI/ARB,2组比较差异有统计学意义(P<0.05)。结论临床药师参与慢性心力衰竭疾病管理能增加β受体阻滞剂和ACEI/ARB的使用率,增加对指南用药的依从性。

作者黄玉玲陈幸谊梁伟杰黄惠敏

机构地区广州市番禺区中心医院药学部广州市番禺区心内科

出处《临床合理用药杂志》 2015年第14期89-90,共2页 Chinese Journal of Clinical Rational Drug Use

基金广州市番禺区科信局立项项目(No:2012-Z-03-26)

关键词心力衰竭疾病管理临床药师随访

分类号 R541.6 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献6

1Dargie H. The CIBIS- II investigators [ J ]. The cardiac insuitieientcy bi- soprolol study II (CIBIS-II ) :a randomised trial. Lancet, 1999,353:9 - 13.
2Wilhnheimer R, van Veldhuisen DJ. Silke B, et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalaprl as compared with the opposite sequence:re- sults of the randomized cardiac insufficiency bisoprolol study (CIBIS) III[ J ]. Circulation ,2005,112 (16) :2426 - 2435.
3Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure : executive sumanaly( update 2005 ) : the task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology [ J ]. Eur Heart J,2005,26 (11 ) :1115 - 1140.
4Heart Failure Society of America. HFSA 2006 Comprehensive Heart Fail- ure Practice Guideline [ J ]. J-Card Fail ,2006,12 (1) :1 -2.
5无.慢性心力衰竭诊断治疗指南[J].中华心血管病杂志,2007,35(12):1076-1095. 被引量：3677
6曹雅旻,胡大一,王宏宇,吴彦.我国基层医院慢性心力衰竭药物治疗现状调查[J].中华内科杂志,2006,45(11):907-909. 被引量：72

二级参考文献51

1王方正,张澍,黄德嘉,华伟,孙宝贵,沈法荣,吴书林,王建安,方全,吴立群,王景峰,王冬梅,郭涛,陈新,中华医学会心电生理和起搏分会心脏再同步治疗专家工作组.心脏再同步治疗慢性心力衰竭的建议[J].中华心律失常学杂志,2006,10(2):90-102. 被引量：90
2Hauptman PJ,Kelly RA.Digitalis.Circulation,1999,99:1265-1270.
3Gheorghiade M.Neurohumoral effects of digoxin:a target for further investigation.Cardiologia,1996,41:967-972.
4The effect of digoxin on mortality and morbidity in patients with heart failure.The Digitalis Investigation Group.N Engl J Med,1997,336:525-533.
5Lechat P,Packer M,Chalon S,et al.Clinical effects of beta-adrenergic blockade in chronic heart failure:a meta-analysis of double-blind,placebo-controlled,randomized trials.Circulation,1998,98:1184-1191.
6Packer M,Coats AJ,Fowler MB,et al.Effect of carvedilol on survival in severe chronic heart failure.N Engl J Med,2001,344:1651-1658.
7Consensus recommendations for the management of chronic heart failure.On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure.Am J Cardiol,1999,83:1A-38A.
8Effects of enalapril on mortality in severe congestive heart failure.Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).The CONSENSUS Trial Study Group.N Engl J Med,1987,316:1429-1435.
9Francis GS,Cohn JN,Johnson G,et al.Plasma norepinephrine,plasma renin activity,and congestive heart failure.Relations to survival and the effects of therapy in V-HeFT II.The V-HeFT VA Cooperative Studies Group.Circulation,1993,87(6 Suppl):V140-148.
10Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.The SOLVD Investigators.N Engl J Med,1991,325:293-302.